PDCD1 and lung carcinoma: In recent years, immunotherapy has become an emerging hot spot in lung cancer treatment, in which programmed cell death receptor1 (PD-1) and immunocheckpoint inhibitors represented by PD-L1 inhibitors have made breakthroughs in the treatment of lung cancer [28].